19:50 IST
BSE
Other Announcement
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Ltd
- Share price
- ₹2,496.30
- Market cap
- ₹1,03,108 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.5×Sector 47.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Merger & Restructuring 10Employee Stock Options 6Other Announcement 5Annual General Meeting 5Management Change 4Earnings Call 4Financial Results 3Debt & Borrowing 3Results Update 2Credit Rating 2Board Meeting Date 2Share Pledge 1Partnership 1Business Update 1Acquisition 1
Time
5 announcements with these filters
13:58 IST
BSE
Other Announcement
Mankind Pharma Other Announcement
Mankind Pharma has received an improved ESG rating of 64 from CRISIL, categorized as 'Strong'. The rating was assigned independently without company engagement.
16:21 IST
BSE
Other Announcement
Mankind Pharma Other Announcement
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) with the exchange. This is a standard periodic disclosure of the company's ownership structure.
18:02 IST
BSE
Other Announcement
Mankind Pharma Other Announcement
Mankind Pharma Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. Issued by M/s Amit Gupta & Associates, the report confirms the company's adherence to SEBI regulations and statutory provisions. This filing is a routine regulatory requirement for listed entities in India.
15:13 IST
BSE
Other Announcement
Mankind Pharma Other Announcement
Mankind Pharma Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The registrar, KFin Technologies, confirmed that no requests for dematerialisation or rematerialisation of shares were received during the quarter.